Candel Therapeutics, Inc. SEC filings CADL
Candel Therapeutics, Inc. has 418 filings in SEC EDGAR's recent list, going back to Feb 16, 2021. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 12, 2026 | — |
| 424B5 | Prospectus supplement | Feb 20, 2026 | — |
| 424B5 | Prospectus supplement | Feb 19, 2026 | — |
| S-3 | Shelf registration | Aug 14, 2025 | — |
| 424B5 | Prospectus supplement | Jun 24, 2025 | — |
| S-8 | Employee stock plan registration | Mar 13, 2025 | — |
| 424B5 | Prospectus supplement | Dec 13, 2024 | — |
| 424B5 | Prospectus supplement | Dec 12, 2024 | — |
| 424B5 | Prospectus supplement | May 24, 2024 | — |
| S-8 | Employee stock plan registration | Mar 28, 2024 | — |
| 424B5 | Prospectus supplement | Feb 13, 2024 | — |
| S-8 | Employee stock plan registration | Mar 30, 2023 | — |
| S-3 | Shelf registration | Aug 5, 2022 | — |
| S-8 | Employee stock plan registration | Mar 29, 2022 | — |
| S-8 | Employee stock plan registration | Jul 29, 2021 | — |
| 424B4 | Prospectus | Jul 28, 2021 | — |
| S-1/A | Amended registration statement | Jul 26, 2021 | — |
| S-1/A | Amended registration statement | Jul 21, 2021 | — |
| S-1/A | Amended registration statement | Jul 16, 2021 | — |
| S-1 | Registration statement | Jun 25, 2021 | — |
Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CADL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Needham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841387
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.